Innovations in Severe Asthma programme


As a leader with a 50-year heritage in respiratory research, we remain relentless in our pursuit to improve the outcomes for patients with severe asthma. 

In clinical practice, identifying patients with severe asthma remains a challenge and their management is often both complex and multifactorial. This is despite an improved understanding of the range of characteristics associated with the disease and the existence of joint ERS/ATS guidelines (ERS/ATS severe asthma guideline ERJ 2014 & Severe asthma: the unmet need and the global challenge, Asthma UK 2017). 

GSK already supports research, societies, patient groups, patient support programmes and medical education in severe asthma. However, the significant knowledge and funding gap in managing all aspects of severe asthma (Severe asthma: the unmet need and the global challenge, Asthma UK 2017) presents a further opportunity to support innovative and targeted initiatives that directly improve the care and lives of those living with severe asthma. 

The GSK “Innovation in Severe Asthma” bursary programme has been initiated to support healthcare and academic organisations to develop innovative projects that address challenges related to the care of patients with severe asthma.

From now until June, GSK are inviting interested individuals and groups to submit their proposals for such projects, so that together we can help severe asthma patients across the UK.

How to submit a proposal

On this page you can find the relevant information you need to develop and submit a proposal. The deadline for submissions is Friday 14th June 2019, please note that submissions received after this will not be considered. This deadline is with a view to successful projects being notified and starting by August/September 2019.

Please note that we are unable to support all types of projects with these bursaries. These bursaries are not intended to provide funding for interventional or non-interventional (prospective or retrospective) studies (definition). Further information, including how to submit proposals for such projects, can be found on GSK’s portal for investigator sponsored studies (

Submissions will first be subject to an initial review to ensure the project aligns with GSK’s governance and compliance processes.

After this there will be a review by an external faculty of two severe asthma experts (Professor Dominick Shaw (Nottingham) and Dr Matthew Masoli (Plymouth) and the GSK UK & Ireland Medical Director, who will award funding to the projects they consider to be truly innovative and of value.


  1. Complete the submission form. Please be sure to complete every section.
  2. Email your completed form to by Friday 14th June
  3. Initial governance/compliance review and communication to unsuccessful applicants
  4. External faculty review
  5. Communication to successful and unsuccessful applicants. 

Please note that all funding will be subject to contracting and disclosures of transfers of value, further information around which will be provided at the time of award.


Professor Dominick Shaw is a clinical academic specialising in campus to clinic research. His main research interest is in severe asthma, but he also carries a wider interest in health-related technology and medical informatics.





Dr Matthew Masoli is a respiratory consultant at the Royal Devon and Exeter Hospital NHS Trust. He has an interest in patients with severe and difficult to control asthma and leads the service which supports specialist asthma services for the South West Peninsula. His current research interests include investigating quality of life impairment and its management in severe asthma. In conjunction with colleagues he has developed a new quality of life questionnaire specifically for use in severe asthma called the severe asthma questionnaire (SAQ).


Dr Karen Mullen is Country Medical Director of GSK for UK and Ireland. She has worked in pharmaceutical medicine for 18 years across Medical Affairs, Clinical Research and Development. Karen has worked across several therapy areas including general medicine, vaccines, gene therapy, she has worked in Australia and USA.